AIM

Business Context and Reporting Period

Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Filing Type: Form 10-Q
Period Ended: September 30, 2010
Business Overview: A specialty pharmaceutical company focused on the clinical development of immune system-enhancing therapies. Key products include Ampligen® (investigational for Chronic Fatigue Syndrome), Alferon N Injection® (FDA-approved for genital warts, currently out of commercial production), and Alferon® LDO (investigational oral formulation for influenza).

Key Financial Metrics

Note: All financial figures are in thousands except per share data. Loss per share was $(0.02) for the quarter and $(0.08) for the nine-month period.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 34% ($819,000) for the quarter and 17% ($1,582,000) for the nine months compared to the prior year periods.
• Expense Growth:
  • R&D: Increased 54% ($635,000) for the quarter, driven by Alferon® LDO clinical costs and the Alferon N Injection® Phase IIb trial in India.
  • G&A: Increased 49% ($574,000) for the quarter, primarily due to stock compensation adjustments and a $188,000 increase in legal fees.
• Revenue Growth: Revenues increased 40% for the quarter and 52% for the nine months, solely from the Ampligen® Cost Recovery Program due to increased patient participation.
• Interest Income: Significant increase in interest and other income ($420,000 for the quarter) due to the investment of excess cash in a diverse portfolio of marketable securities.
• Cash Position: Cash and cash equivalents decreased from $58,072 (Dec 31, 2009) to $3,044 (Sep 30, 2010), offset by the acquisition of $45,217 in marketable securities.

Guidance, Outlook, Risks, and Contingencies

Management Commentary and Outlook

• Ampligen®: Received a Complete Response Letter (CRL) from the FDA in November 2009. The FDA requires an additional confirmatory clinical study (approx. 300 patients, 6 months duration) and rodent carcinogenicity studies. Management is planning this study.
• Alferon N Injection®: Commercial sales halted since March 2008 due to inventory expiration. Manufacturing upgrades are underway; product availability for commercial sales is estimated for mid-to-late 2011.
• Alferon® LDO: Clinical study for influenza is on "Clinical Hold" by the FDA due to Chemistry, Manufacturing, and Controls (CMC) issues regarding product stability. New stability data is expected to be submitted to the FDA by the end of December 2010.
• Liquidity: The company has approximately $48.3 million in liquid assets. It maintains an At-The-Market (ATM) equity program to sell up to 32 million shares, though no shares were sold in the quarter ended September 30, 2010.

Risks and Contingencies

• Legal Proceedings:
  • JCI Judgment: Won an $188 million judgment against Johannesburg Consolidated Investments in August 2010; collection efforts are ongoing.
  • Securities Class Action: Entered into a settlement agreement in principle regarding securities class actions alleging misrepresentation of the Ampligen® NDA status. The settlement is expected to be paid via insurance, with no direct cost to the company.
  • Other Litigation: Ongoing suits involving MidSouth Capital, Cato Capital, and shareholder derivative complaints.
• Regulatory Risk: Failure to obtain FDA approval for Ampligen® or resolve the Clinical Hold on Alferon® LDO would materially adversely affect operations.
• Capital Constraints: The company has a limited number of authorized but unissued shares (approx. 32 million), which may hinder future equity financing.

Key Facts for Investor Verification

• Regulatory Status of Ampligen®: Verify the timeline and design of the additional clinical study required by the FDA to address the November 2009 CRL.
• Alferon® LDO Clinical Hold: Confirm the submission date of the new stability data to the FDA and the likelihood of the Clinical Hold being lifted by the end of 2010.
• Manufacturing Timeline: Validate the projected mid-to-late 2011 availability of Alferon N Injection® for commercial sale and the status of vendor agreements for formulation and packaging.
• Legal Collection: Monitor the progress of collecting the $188 million judgment against Johannesburg Consolidated Investments.
• Cash Burn Rate: Assess the sustainability of the current cash position ($48.3M) against the burn rate of approximately $10M per nine months, considering the need for additional clinical trials.